PRODUCT INFORMATION

PF-04929113

Item No. 18270

CAS Registry No.:	908115-27-5
Formal Name:	glycine, *trans*-4-[[2-(aminocarbonyl)-5-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]phenyl]amino]cyclohexyl ester
Synonym:	SNX-5422
MF:	$C_{25}H_{30}F_3N_5O_4$
FW:	521.5
Purity:	≥98%
UV/Vis.:	λ_{max}: 250, 359 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-04929113 is supplied as a crystalline solid. A stock solution may be made by dissolving the PF-04929113 in the solvent of choice, which should be purged with an inert gas. PF-04929113 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of PF-04929113 in these solvents is approximately 1 and 0.25 mg/ml, respectively.

PF-04929113 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PF-04929113 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PF-04929113 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PF-04929113 is a prodrug for the Hsp90 inhibitor, PF-04928473 (SNX-2112), which binds both Hsp90α and Hsp90β with an IC_{50} value of 30 nM.[1,2] The prodrug, PF-04929113, is rapidly absorbed and converted into the active inhibitor after oral administration.[2] The active inhibitor causes degradation of Hsp90 client proteins, including HER2, and reduces phosphorylation of downstream kinases, including Akt and ERK1/2, leading to apoptosis in cancer cells.[1,3] Oral administration of the prodrug, PF-04929113, reduces tumor growth and prolongs survival in mouse models of multiple myeloma and prostate cancer.[3,4]

References

1. Chandarlapaty, S., Sawai, A., Ye, Q., *et al.* SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. *Clin. Cancer Res.* **14(1)**, 240-248 (2008).
2. Jain, L., Gardner, E.R., Venitz, J., *et al.* Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **878(30)**, 3187-3192 (2010).
3. Okawa, Y., Hideshima, T., Steed, P., *et al.* SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK Blood. **113(4)**, 846-855 (2009).
4. Lamoureux, F., Thomas, C., Yin, M.-J., *et al.* A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. *Clin. Cancer Res.* **17(8)**, 2301-2313 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM